Newport Pain ManagementMedical Corp

Newport Pain Management

1401 Avocado Avenue, Suite 101

Newport Beach, CA 92660

Phone: (949) 759-8400

Effective Date: September 11, 2026


Off-Label Prescription Disclosure

Why this disclosure exists

Patients receiving care at Newport Pain Management may be prescribed medications for uses that have not been specifically approved by the United States Food and Drug Administration (FDA) for those particular purposes. This practice, called "off-label prescribing," is common, legal, ethical, and often supported by strong clinical evidence — but it is a source of confusion for many patients. This disclosure explains what off-label prescribing is, why it is common in pain management, and what you have a right to know about your own medications.

What off-label prescribing means

When a pharmaceutical company develops a new medication, the FDA approves it for one or more specific uses based on the studies the company has submitted. These approved uses are described on the medication's official labeling. Once a medication is FDA-approved for any use, physicians may legally prescribe it for other uses based on clinical evidence, medical literature, and their own professional judgment. Prescribing a medication for a use not on its FDA label is called off-label prescribing.

Off-label does not mean experimental. It does not mean unproven. It does not mean unsafe. It simply means that the specific use has not gone through the formal FDA approval process for that particular indication. Many off-label uses are supported by extensive clinical evidence, are recognized in medical guidelines, are recommended by specialty societies, and are considered standard of care by physicians in the relevant field.

Why off-label prescribing is common in pain management

Pain management is one of the medical specialties where off-label prescribing is most common. Several factors contribute to this:

  • Many medications now understood to be effective for pain were originally developed for other purposes (depression, seizures, blood pressure) and their pain applications were discovered later.
  • The FDA approval process focuses on the original indications a company pursues. Pharmaceutical companies often do not seek expensive additional approvals for secondary uses even when the medication is known to work for them.
  • Chronic pain conditions are heterogeneous — the same medication may work well for one type of pain and poorly for another, and clinical practice has developed nuanced understanding of these distinctions that the FDA labeling does not capture.
  • Newer medications with broader pain indications are often expensive; older off-label options may be equally effective at much lower cost, and pain specialists frequently choose them for this reason.

Common examples of off-label prescribing in pain management

The following are examples of medications commonly prescribed off-label in pain management. This list is not exhaustive and does not describe every possible use of these medications. These are educational examples, not recommendations that any specific patient receive any specific medication.

Gabapentin and pregabalin (gabapentinoids)

Gabapentin is FDA-approved for postherpetic neuralgia (the persistent pain that can follow shingles) and for the treatment of partial seizures. It is commonly prescribed off-label for many other types of neuropathic pain, including diabetic neuropathy, chemotherapy-induced neuropathy, radiculopathy (pinched nerve pain), post-surgical neuropathic pain, and complex regional pain syndrome. Pregabalin has more pain indications on its FDA label but is also used off-label for conditions beyond those specifically approved.

Tricyclic antidepressants

Medications such as amitriptyline, nortriptyline, and desipramine are FDA-approved for depression. At doses well below those used for depression, they are among the most effective medications for neuropathic pain, chronic tension-type headache prevention, migraine prevention, and certain other chronic pain conditions. These off-label uses have been standard clinical practice for decades and are supported by extensive research.

Serotonin-norepinephrine reuptake inhibitors (SNRIs)

Duloxetine has FDA approvals for depression, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. It is also used off-label for other chronic pain conditions such as chemotherapy-induced neuropathy and central pain syndromes. Venlafaxine is FDA-approved for depression and anxiety disorders and is commonly used off-label for migraine prevention and neuropathic pain.

Muscle relaxants

Most muscle relaxants (cyclobenzaprine, methocarbamol, tizanidine, others) are FDA-approved for short-term treatment of acute musculoskeletal conditions. Ongoing use for chronic pain conditions is off-label but common in clinical practice when clinically justified.

Ketamine

Ketamine is FDA-approved as an anesthetic agent. It is used off-label at sub-anesthetic doses for treatment-resistant depression, chronic pain conditions including complex regional pain syndrome and refractory neuropathic pain, and certain other conditions. The esketamine formulation (Spravato) has specific FDA approval for treatment-resistant depression; racemic ketamine (used at our KetaCure Ketamine Infusion Center) is used off-label for both pain and depression indications.

Low-dose naltrexone

Naltrexone is FDA-approved at standard doses for the treatment of opioid and alcohol dependence. At much lower doses (approximately one-tenth the standard dose), it is used off-label for certain chronic pain conditions including fibromyalgia, complex regional pain syndrome, and inflammatory pain conditions, with emerging evidence supporting its use.

Topical medications

Compounded topical creams and gels containing combinations of pain-active ingredients (such as ketamine, gabapentin, lidocaine, amitriptyline, or others) are typically off-label in their formulation and application. Compounded topicals can offer targeted pain relief with less systemic exposure than oral medications and are used for various localized chronic pain conditions.

Others

Other medications used off-label in pain management include certain blood pressure medications (clonidine, propranolol) for pain and headache indications, certain antiseizure medications beyond their approved indications, and various other medications where clinical evidence supports off-label use.

Legal and regulatory context

Off-label prescribing is legal in the United States and is a well-established part of medical practice. The FDA regulates the marketing and labeling of medications but does not regulate the practice of medicine itself. Physicians are expected to exercise independent professional judgment about how best to treat their patients, informed by the medical literature, clinical experience, and the specific circumstances of each patient. When a physician prescribes a medication off-label based on legitimate clinical judgment, they are practicing medicine, not violating the law.

Off-label prescribing is recognized as standard practice by every major medical specialty society, is discussed extensively in medical literature and clinical guidelines, and is taught in every medical training program in the United States.

Your rights as a patient

When your physician prescribes a medication for you, you have the right to know:

  • What medication is being prescribed
  • What condition it is being prescribed for
  • Whether the use is on-label or off-label
  • Why the medication was chosen for your situation
  • What the expected benefits are
  • What the possible side effects and risks are
  • What alternatives exist and how they compare

If a medication is being prescribed off-label, your physician should be able to explain the clinical reasoning behind the choice and the evidence supporting it. This conversation is a normal and appropriate part of thoughtful prescribing.

Insurance coverage considerations

Insurance coverage of off-label prescriptions varies by insurer and by medication. Some insurers cover well-established off-label uses without difficulty. Others require prior authorization or documentation of the clinical reasoning. In some cases, off-label prescriptions are not covered by insurance, particularly for newer or more expensive medications used off-label.

If your insurance does not cover an off-label prescription and this creates a financial obstacle, please discuss this with our office. We can often help by providing appropriate clinical documentation to the insurer, considering alternative medications that may be covered, or discussing patient assistance programs where available.

Consent to off-label prescribing

By accepting a prescription for a medication being used off-label, you acknowledge that the off-label nature of the prescription has been disclosed to you (through this document, in conversation with your physician, or both), that you have had the opportunity to ask questions, and that you understand that the prescription is based on your physician's clinical judgment rather than on a specific FDA approval for your particular use.

This does not diminish your right to receive further information, to seek a second opinion, or to decline the prescription. It reflects the reality that off-label prescribing is a normal part of pain management practice and requires informed patient participation.

Questions

If you have questions about a specific medication being prescribed for you, whether a use is on-label or off-label, or the clinical reasoning behind a prescribing choice, please raise them with Dr. Scott at your visit or contact our office. Understanding your medications is an essential part of using them safely and effectively.

Contact us

Questions about this Off-Label Prescription Disclosure may be directed to:

Newport Pain Management

1401 Avocado Avenue, Suite 101

Newport Beach, CA 92660

Phone: (949) 759-8400

Website: newportpain.com

Changes to this Off-Label Prescription Disclosure

We may update this Off-Label Prescription Disclosure from time to time to reflect changes in our practices, applicable law, or the services we provide. Any updates will be posted on this page with a revised Effective Date. Substantive changes will be highlighted in a prominent notice on our website for a reasonable period after the change takes effect. Continued use of our website or services after changes take effect constitutes acceptance of the updated Off-Label Prescription Disclosure.


Effective as of September 11, 2026